-
公开(公告)号：US11435355B2
公开(公告)日：2022-09-06
申请号：US16068938
申请日：2017-01-04
发明人： Andras Fiser , Enghui Yap
IPC分类号： G01N33/574 , G16B15/30 , G06F3/14
摘要： A system and a method for identifying a cognate ligand molecules for known proteins.
-
公开(公告)号：US20220275027A1
公开(公告)日：2022-09-01
申请号：US17753299
申请日：2019-08-28
发明人： TOM W. MUIR , ADAM STEVENS , JOSEF GRAMESPACHER , DAVID COWBURN , GIRIDHAR SEKAR
摘要： The present disclosure relates to atypical split N- and C-inteins and variants thereof. This disclosure also relates to complexes comprising the split N- or C-inteins of this disclosure and a compound of interest and compositions comprising said complexes. In addition, this disclosure relates to methods of using the atypical split N- and C-inteins.
-
公开(公告)号：US11407806B2
公开(公告)日：2022-08-09
申请号：US16603306
申请日：2018-04-02
发明人： Harris Goldstein , Steven C. Almo
摘要： Compositions and methods to increase the in vivo capacity of CD8+ T cells to kill HIV-infected and reactivated latent HIV-infected T cells (LHITC) to functionally cure HIV infection or improve the clinical course. Compositions and methods to increase the in vivo capacity of CD8+ T cells to kill CMV or CMV-infected cells are also provided.
-
公开(公告)号：US20220213462A1
公开(公告)日：2022-07-07
申请号：US17605864
申请日：2020-04-17
发明人： Eric Bouhassira , Khulan Batbayar , Karl Roberts
IPC分类号： C12N9/64 , A61K35/18 , C12N5/078 , A61P7/02 , C07K14/745
摘要： This disclosure provides methods and compositions for treating TTP based on transfusion of a relatively small number of genetically modified red blood cells. The genetically modified red blood cells express a fusion protein including a fragment of ADAMTS13 that is enzymatically active against von Willebrand factor (VWF). The fragments of ADAMTS13 can be resistant to the inhibitors, e.g., the auto-immune antibodies, which are responsible for the acquired form of TTP.
-
公开(公告)号：US20220142947A1
公开(公告)日：2022-05-12
申请号：US17565556
申请日：2021-12-30
发明人： Joel M. Friedman
IPC分类号： A61K31/12 , A61K31/352 , A61K31/4375 , A61K31/05 , A61K31/593 , A61K47/10 , A61K47/12 , A61K9/00 , A61P37/06 , A61K9/06
摘要： A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions by enhancing systemic level of nitric oxide.
-
公开(公告)号：US20220098274A1
公开(公告)日：2022-03-31
申请号：US17306435
申请日：2021-05-03
发明人： Jonathan R. Lai , Steven Almo , Nina Liu , Julia Frei
IPC分类号： C07K14/735 , C07K14/47 , C07K14/705 , A61P31/00 , A61P35/00 , A61K38/17 , C12N15/62
摘要： Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.
-
公开(公告)号：US11242378B2
公开(公告)日：2022-02-08
申请号：US16896980
申请日：2020-06-09
发明人： Zachary A. Bornholdt , Larry Zeitlin , Kartik Chandran , Anna Wec , Laura Walker
摘要： Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially, similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
-
公开(公告)号：US20210387953A1
公开(公告)日：2021-12-16
申请号：US17283613
申请日：2019-10-10
IPC分类号： C07D263/57 , C07D413/12
摘要： Compounds and pharmaceutically acceptable salts thereof of Formula I are disclosed. The variables, e.g. R1-R9, X, and Y are defined herein. Certain compounds and salts of Formula I are active as CMA modulators. The disclosure provides pharmaceutical compositions containing a compound of Formula I and methods of treating disorders responsive to CMA modulation.
-
公开(公告)号：US20210332141A1
公开(公告)日：2021-10-28
申请号：US16640006
申请日：2018-08-30
发明人： Pedro Beltran , Derek Huffman , Nir Brazilal , Pinchas Cohen
IPC分类号： C07K16/28 , A61K45/06 , A61K31/155 , A61K39/395 , A61K31/566 , A61P5/30
摘要： The present disclosure provides a method of improvement, preservation, prophylaxis, or inhibition-of-deterioration of a healthspan parameter of a mammalian subject. In exemplary embodiments, the method comprises administering to the subject a composition that comprises an insulin-like growth factor-1 receptor (IGF-1 R) inhibitor, wherein the composition is administered in an amount effective to improve, provide prophylaxis for, or inhibit-the-deterioration of the healthspan parameter.
-
公开(公告)号：US20210322482A1
公开(公告)日：2021-10-21
申请号：US16327402
申请日：2017-08-21
发明人： Hui B. Sun
摘要： Microvesicles produced by stem cells grown on a silk scaffold for enhancing stem cell self-renewal/proliferation and promoting tenogenesis in damaged tendons, and their use in tendon wound repair and tendinopathy treatment. Also provided are compositions containing the microvesicles and devices for obtaining them.
-
-
-
-
-
-
-
-
-
搜索结果
474 条记录 (耗时 0.035 秒)
